22,872 Shares in Accuray Incorporated (NASDAQ:ARAY) Acquired by Intech Investment Management LLC

Intech Investment Management LLC purchased a new position in Accuray Incorporated (NASDAQ:ARAY) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 22,872 shares of the medical equipment provider’s stock, valued at approximately $41,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Armistice Capital LLC acquired a new stake in Accuray during the second quarter worth approximately $910,000. Los Angeles Capital Management LLC purchased a new position in shares of Accuray in the 3rd quarter valued at $418,000. Connor Clark & Lunn Investment Management Ltd. raised its stake in Accuray by 489.1% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 277,859 shares of the medical equipment provider’s stock worth $500,000 after acquiring an additional 230,695 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in Accuray by 127.1% in the third quarter. Assenagon Asset Management S.A. now owns 164,999 shares of the medical equipment provider’s stock valued at $297,000 after acquiring an additional 92,357 shares during the last quarter. Finally, Perritt Capital Management Inc boosted its stake in Accuray by 139.3% in the second quarter. Perritt Capital Management Inc now owns 120,000 shares of the medical equipment provider’s stock valued at $218,000 after acquiring an additional 69,864 shares in the last quarter. Institutional investors and hedge funds own 64.08% of the company’s stock.

Wall Street Analyst Weigh In

Separately, StockNews.com cut Accuray from a “buy” rating to a “hold” rating in a research report on Friday, November 15th.

Accuray Price Performance

Shares of NASDAQ ARAY opened at $2.09 on Tuesday. The stock has a fifty day moving average price of $1.89 and a 200 day moving average price of $1.87. Accuray Incorporated has a 1-year low of $1.40 and a 1-year high of $3.05. The company has a debt-to-equity ratio of 3.59, a current ratio of 1.63 and a quick ratio of 0.87. The company has a market cap of $210.19 million, a PE ratio of -12.29 and a beta of 1.44.

Accuray (NASDAQ:ARAY) last issued its earnings results on Wednesday, November 6th. The medical equipment provider reported ($0.04) earnings per share for the quarter, meeting the consensus estimate of ($0.04). The business had revenue of $101.55 million for the quarter, compared to the consensus estimate of $98.10 million. Accuray had a negative net margin of 3.72% and a negative return on equity of 36.93%. During the same quarter in the previous year, the firm earned ($0.03) earnings per share. Sell-side analysts forecast that Accuray Incorporated will post 0.01 EPS for the current year.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.